Seeking Alpha Quant rates LABU as a strong Sell, but I rates it as a Buy due to bullish market conditions. LABU is a leveraged ETF that seeks to track 3x the daily performance of the S&P ...

LABU is a 3X leveraged fund that has disappointed the biotech bulls. The sector looks beaten and perhaps cheap relative to long-term prospects. LABU can work for medium term returns if two ...

Sean Ross is a strategic adviser at 1031x.com, Investopedia contributor, and the founder and manager of Free Lances Ltd. The Direxion Daily S&P Biotech Bull 3X Fund (NYSEARCA: LABU) is an exchange ...

Speaking of moving higher, there is the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU). After last week's 13% percent gain, LABU is up about 43 percent month-to-date, good for the best ...

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. This ETF attempts to mimic 3X the ...

For the Daily S&P Biotech Bull 3X Shares ETF (Symbol: LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $118.67 per unit. With LABU trading at ...